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Percutaneous Revascularisation in Diabetic Patients with Coronary
Artery Disease
WAI-HONG CHEN, CHU-PAK LAU
From Division of Cardiology, Department of Medicine, The University of Hong Kong, Queen Mary Hospital,
Hong Kong
CHEN and LAU: Percutaneous Revascularisation in Diabetic Patients with Coronary Artery Disease. Diabetic
patients with coronary artery disease are associated with an unfavourable long-term outcome. Surgical
revascularisation on top of medical therapy has been shown to confer survival benefit in patients with mutivessel and
left main disease. With the emergence of the percutaneous approach of revascularisation, several clinical trials have
been conducted to compare these two modalities of treatment. Consistent results were demonstrated in the diabetic
subgroup that coronary artery bypass grafting is superior to balloon angioplasty in preventing late adverse cardiac
event. With the advancement of percutaneous technique using coronary stenting as the predominant mode of catheterbased revascularisation, the latest comparison trial showed that stenting is a comparable alternative but is associated
with a higher incidence of repeat revascularisation than bypass surgery. However, the debate is not yet settled
because of the promising results of platelet glycoprotein IIb/IIIa antagonists and drug-eluting stents in improving
the safety and efficacy of percutaneous intervention. It remains to be proven by ongoing clinical trials the best
revascularisation strategy for diabetics with multivessel coronary disease. (J HK Coll Cardiol 2002;10:114-119)
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IIb/IIIa

Following randomised clinical trials (RCTs) in
the 70's that showed the benefits of coronary artery
bypass graft (CABG) over medical treatment alone
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in certain subsets of patients with multivessel
coronary artery disease (CAD) and left main stem
disease, CABG has been regarded as the "standard"
treatment for these patients. With improvements in
expertise and technology, percutaneous transluminal
coronary angioplasty (PTCA) evolves from the
treatment of simple, focal, proximally located lesions
in a single vessel to those complex anatomic subsets
previously tackled only by cardiac surgeons.
In the late 1980's, six RCTs were undertaken
to compare PTCA and CABG as the revascularisation
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procedure in patients with multivessel CAD. The
main results were consistent among the trials.
Mortality was not significantly different between the
two modalities of treatment (Figure 1). Fewer repeat
revascularisations and recurrent angina were
achieved by CABG. A trend of reduction of
myocardial infarction (MI) was seen in patients
undergoing PTCA. 1-6 However, there are two
exceptions to the overall trial results. The Bypass
Angioplasty Revascularization Investigation (BARI)
trial showed that treated diabetics had a distinct
survival advantage with CABG. The benefit was seen
6 months after randomisation and the survival curve
continued to diverge up to 7 years of follow-up.
Survival was 76.4% for the CABG group and 55.7%
for the PTCA group at 7 years (p=0.0011). 7 The

Emory Angioplasty Versus Surgery Trial (EAST)
also showed a trend of better survival among diabetics
treated with CABG. Eight-year survival was 75.5%
in the CABG group and 60.1% in the PTCA group.8

Poor Outcome of Diabetics After
Revascularisation
Diabetes mellitus is associated with the early
initiation and accelerated progression of coronary
atherosclerosis. Diabetics constitute a significant
proportion of patients requiring revascularisation for
the treatment of advanced coronary artery disease.
Patients with diabetes are at increased risk of adverse
outcome after PTCA. In the early era of balloon

Figure 1. Survival of diabetic patients with multivessel coronary artery disease after percutaneous
transluminal coronary angioplasty or coronary artery bypass graft surgery in randomized controlled trials.
BARI = Bypass Angiolasty Revascularization Investigation; CABG = Coronary Artery Bypass Graft; CABRI
= Coronary Angioplasty versus Bypass Revascularisation Investigation; EAST = Emory Angioplasty versus
Surgery Trial; ERACI = Argentine Randomized Trial of Percutaneous Transluminal Coronary Angioplasty
versus Coronary Artery Bypass Surgery in Multivessel Disease; GABI = German Angioplasty Bypass Surgery
Investigation; RITA = Randomised Intervention Treatment of Angina; PTCA = Percutaneous Transluminal
Coronary Angioplasty.
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angioplasty, diabetic patients had more in-hospital
mortality or myocardial infarction (MI) compared
with patients without diabetes. The long-term
outcome is also plagued by increased risk of
restenosis, contributing to greater rates of mortality,
MI, and repeat revascularisation.9,10
The presence of diabetes is also associated with
a higher event rate after CABG. 11 Diabetic patients
have more rapid disease progression in saphenous
vein grafts and in native vessels whether grafted or
not. 12 Diabetes is also an independent risk factor of
late mortality after CABG.13
Metabolic and haematologic derangements
contribute to the increased incidence of adverse
cardiac events after revascularisation in diabetics.14
Platelets are more often activated with increased
aggregability, enhanced secretion of vasoconstrictive
agents, and greater mitogenic activity. Fibrinogen,
factor VII and plasminogen activator inhibior-1 levels
are increased while antithrombin III activity is
reduced. Diabetes is associated with endothelial
dysfunction and excessive smooth muscle cell
proliferation and extracellular matrix formation.15
The reasons for the inferiority of PTCA
compared with CABG for coronary revascularisation
in diabetics are usually attributed to a high restenosis
rate, incomplete revascularisation, and progression
of atherosclerosis. Improvements in the techniques
of both percutaneous and surgical techniques have
made it necessary to re-examine this issue from time
to time. This is especially true for percutaneous
intervention as changes in practice are occurring
rapidly over the last few years.

Stenting: Improvement
over Balloon Angioplasty
Balloon angioplasty is largely replaced by
coronary stent implantation as the predominant
modality of percutaneous revascularisation because
of the advantages of reduction in emergency CABG
and restenosis.16,17 CABG has also undergone changes
with the routine use of arterial conduits that has better
long-term patency.18 The Arterial Revascularization
Therapy Study (ARTS) was undertaken to compare
contemporary percutaneous and surgical
revascularisation for the treatment of patients with
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multivessel CAD. In the diabetic subgroup, the 1year incidence of the individual components or the
composite of death, MI, or stroke was similar between
the two groups. The main difference was the
increased need for repeat revascularisation in the stent
group (14.3% vs 3.1%; p <0.001). 19 Although the
reintervention rate has been reduced by ~50%
compared with balloon angioplasty results in prior
comparison trials, coronary stenting in diabetics is
still associated with a high rate of restenosis and the
resulting need for repeat revascularisation,
confirming the results of retrospective series which
reported poorer outcomes of diabetics after stent
implantation compared to nondiabetics.20,21 Moreover,
the mortality was 6.4% for the stent group and 3.1%
for the surgery group, although not reaching
statistical significance. From the BARI and EAST
experience, a longer follow-up may unmask the
mortality difference between the two groups.

Platelet Glycoprotein IIb/IIIa
Antagonist: Reduction in Mortality
and Repeat Revascularisation
Another important advance in percutaneous
revascularisation emerges from the use of platelet
glycoprotein (GP) IIb/IIIa antagonists. In particular,
abciximab has been shown to reduce ischaemic
cardiac events following balloon angioplasty,
artherectomy, and stent implantation. 22-24 In the
Evaluation of Platelet IIb/IIIa Inhibitor for Stenting
Trial (EPISTENT) diabetic substudy, the 6-month
target vessel revascularisation (TVR) rate was
significantly reduced from 16.6% in the stent-placebo
group to 8.1% in the abciximab-stent group. 25
Angiographic analysis showed a significant decrease
in the late loss index. The data are suggesting an antirestenotic effect of abciximab which may be related
to its non-specific inhibitory effects on integrin
receptors including IIb/IIIa, αv β3 and Mac-1, which
have been implicated in the thrombotic and
proliferative response leading to neointima formation
after arterial injury.26-29 In addition to TVR reduction,
evidence of mortality reduction was observed in the
EPISTENT trial when abciximab was used as adjunct
during coronary stenting. 30 Meta-analysis of
Evaluation of 7E3 for the Prevention of Ischemic
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Complications (EPIC), Evaluation in PTCA to
Improve Long-term Outcome with abciximab GP IIb/
IIIa blockade (EPILOG), and EPISTENT
demonstrated a survival benefit in diabetic patients
receiving abciximab during elective or urgent
percutaneous intervention. A 44% mortality reduction
at 1 year from 4.5% to 2.5% was found. 31 The
combination of abciximab and stenting should be
considered in diabetic patients undergoing
percutaneous revascularisation because of the
significant reduction in mortality, MI and reintervention and should be adopted for future
comparison trials.

Drug-eluting Stents: Reduction of
Restenosis; Complete Revascularisation
Enormous efforts have been invested in the
attempt to reduce restenosis soon after the inception
of PTCA. Among the numerous devices and drugs
that have been tested, stents were shown in the early
1990s to be the first device capable of reducing
restenosis compared with balloon angioplasty. The
improved but still disappointing rate of in-stent
restenosis (ISR) especially in diabetic patients was
the impetus for continued effort to overcome this
enemy of percutaneous revascularisation. Although
proven to be an effective treatment for ISR, vascular
brachytherapy was disappointingly unsuccessful in
diminishing restenosis when applied to de novo
lesions after coronary angioplasty or stenting. 32
Following early promising results of reduction in
restenosis in animal models, 33-35 a pilot study with
the sirolimus-eluting stent was shown to achieve 0%
ISR up to 1-year angiographic follow-up in 29
patients.36 The dramatic result of ISR reduction was
recently joined by the Randomised double-blind
study with the Sirolimus-eluting Bx VElocity
balloon expandable stent in the treatment of patients
with de novo native coronary artery lesions (RAVEL)
which showed again no ISR at 6 months in patients
receiving sirolimus-eluting stents. The diabetic
subgroup in RAVEL is no exception to this
remarkable anti-restenotic effect of sirolimus. The
ISR was 0% in the sirolimus-eluting stent group
versus 42% in the bare stent group. 37 Many other
medications including paclitaxol and actinomycin-

J HK Coll Cardiol, Vol 10

D are being tested in clinical trials of drug-eluting
stents. The TAXUS I trial using paclitaxol-eluting
NIR stents also demonstrated a promising 0%
ISR. 38 When the safety and efficacy are confirmed
by longer-term follow-up, the new era of
percutaneous revascularisation will begin. Small
vessels, long lesions, bifurcations, and unprotected
left main stenosis can be confidently tackled by drugeluting stents with little hindrance from the worry of
restenosis. A more complete revascularisation
comparable to CABG may be achieved by the
percutaneous approach. With development in the
technology of detecting vulnerable plaques, 39 e.g.
optical coherence tomography, thermography,
elastography, those haemodynamically insignificant
but unstable lesions may be prophylactically stented
for the prevention of future coronary events from
plaque disruption.

Conclusion
Advances in interventional cardiology will
most likely impact upon the shortcomings of catheterbased revascularisation in diabetics. Equipped with
GP IIb/IIIa antagonists and drug-eluting stents,
interventional cardiologists are ready again for
another comparison trial with CABG. The ARTS-2
is underway to compare percutaneous revascularisation
incorporating these improvements with CABG in
patients with multivessel disease. The best
revascularisation strategy for diabetic patients with
multivessel CAD remains to be elucidated by ongoing
clinical trials.
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